SheMed is introducing a medical approach that breaks with traditional models of women’s health. While most telehealth platforms base their diagnoses on self-reported information, the London-based startup relies on biological analyses to tailor treatments to each patient — restoring the central role of clinical data in a field long dominated by standardized approaches.
At the core of its model is the use of biomarkers and comprehensive blood tests to determine eligibility for GLP-1 treatments, a class of drugs popularized by Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly). Originally developed for diabetes management, these medications are now used for metabolic care and weight loss. By integrating biological results into the prescription process, SheMed aims to move beyond the simplifying logic of BMI, often criticized for its lack of reliability in assessing women’s health.
This approach reflects a broader shift toward personalized medicine. SheMed’s care pathway combines practitioner-led medical supervision, continuous digital monitoring tools, and psychological support. The goal is to connect the physiological and behavioral dimensions of women’s metabolic health while respecting each patient’s hormonal variability.
The company plans to publish this month the results of the first European clinical trial focused on the impact of GLP-1 drugs on women’s hormonal and metabolic health. Conducted among thousands of users, this study is expected to identify differentiated responses based on biological profiles and could help redefine metabolic-care protocols historically modeled on male physiology.
Founded in April 2024 in London by sisters Olivia and Chloe Ferro, SheMed has raised €43 million ($50 million) in a Series A round to expand its operations across the United Kingdom, strengthen its medical teams, and support its research programs. The platform now counts over 60,000 members and aims to improve access to preventive, data-driven healthcare designed around women’s specific needs.
